Header Logo

Connection

Alan Landay to Anti-Retroviral Agents

Back to Details
This is a "connection" page, showing publications Alan Landay has written about Anti-Retroviral Agents.
Alan Landay
Connection Strength
4.215
Anti-Retroviral Agents
  1. Short communication: Apoptosis pathways in HIV-1-infected patients before and after highly active antiretroviral therapy: relevance to immune recovery. AIDS Res Hum Retroviruses. 2015 Feb; 31(2):208-16.
    View in: PubMed
    Score: 0.476
  2. HIV RNA levels in plasma and cervical-vaginal lavage fluid in elite controllers and HAART recipients. AIDS. 2014 Mar 13; 28(5):739-43.
    View in: PubMed
    Score: 0.454
  3. A role for TLR signaling during B cell activation in antiretroviral-treated HIV individuals. AIDS Res Hum Retroviruses. 2013 Oct; 29(10):1353-60.
    View in: PubMed
    Score: 0.436
  4. HIV: so near and yet so far. Curr HIV/AIDS Rep. 2013 Mar; 10(1):1-2.
    View in: PubMed
    Score: 0.423
  5. Immunophenotypic alterations in acute and early HIV infection. Clin Immunol. 2007 Dec; 125(3):299-308.
    View in: PubMed
    Score: 0.291
  6. Immunophenotypic markers and antiretroviral therapy (IMART): T cell activation and maturation help predict treatment response. J Infect Dis. 2004 May 15; 189(10):1811-20.
    View in: PubMed
    Score: 0.229
  7. Phospholipid Metabolism Is Associated with Time to HIV Rebound upon Treatment Interruption. mBio. 2021 02 23; 12(1).
    View in: PubMed
    Score: 0.184
  8. Maintenance of Viral Suppression in Human Immunodeficiency Virus Controllers Despite Waning T-Cell Responses During Antiretroviral Therapy. J Infect Dis. 2020 11 09; 222(11):1837-1842.
    View in: PubMed
    Score: 0.180
  9. Elevated Plasma Ceramides Are Associated With Antiretroviral Therapy Use and Progression of Carotid Artery Atherosclerosis in HIV Infection. Circulation. 2019 04 23; 139(17):2003-2011.
    View in: PubMed
    Score: 0.162
  10. Gut microbiota and plasma metabolites associated with diabetes in women with, or at high risk for, HIV infection. EBioMedicine. 2018 Nov; 37:392-400.
    View in: PubMed
    Score: 0.156
  11. Changes in Inflammation but Not in T-Cell Activation Precede Non-AIDS-Defining Events in a Case-Control Study of Patients on Long-term Antiretroviral Therapy. J Infect Dis. 2018 06 20; 218(2):239-248.
    View in: PubMed
    Score: 0.153
  12. Polymorphism rs1385129 Within Glut1 Gene SLC2A1 Is Linked to Poor CD4+ T Cell Recovery in Antiretroviral-Treated HIV+ Individuals. Front Immunol. 2018; 9:900.
    View in: PubMed
    Score: 0.152
  13. Can Biomarkers Advance HIV Research and Care in the Antiretroviral Therapy Era? J Infect Dis. 2018 01 30; 217(4):521-528.
    View in: PubMed
    Score: 0.149
  14. CD4 enumeration technologies: a systematic review of test performance for determining eligibility for antiretroviral therapy. PLoS One. 2015; 10(3):e0115019.
    View in: PubMed
    Score: 0.122
  15. Association of subclinical atherosclerosis with lipid levels amongst antiretroviral-treated and untreated HIV-infected women in the Women's Interagency HIV study. Atherosclerosis. 2012 Dec; 225(2):408-11.
    View in: PubMed
    Score: 0.103
  16. Potential cardiovascular disease risk markers among HIV-infected women initiating antiretroviral treatment. J Acquir Immune Defic Syndr. 2012 Aug 01; 60(4):359-68.
    View in: PubMed
    Score: 0.102
  17. Delaying a treatment switch in antiretroviral-treated HIV type 1-infected patients with detectable drug-resistant viremia does not have a profound effect on immune parameters: AIDS Clinical Trials Group Study A5115. AIDS Res Hum Retroviruses. 2009 Feb; 25(2):135-9.
    View in: PubMed
    Score: 0.080
  18. Determinants of CD4+ T cell recovery during suppressive antiretroviral therapy: association of immune activation, T cell maturation markers, and cellular HIV-1 DNA. J Infect Dis. 2006 Jul 01; 194(1):29-37.
    View in: PubMed
    Score: 0.066
  19. Distinct mechanisms of T cell reconstitution can be identified by estimating thymic volume in adult HIV-1 disease. J Infect Dis. 2005 Nov 01; 192(9):1577-87.
    View in: PubMed
    Score: 0.063
  20. Obesity in HIV infection: host-pathogen interaction. AIDS. 2022 09 01; 36(11):1477-1491.
    View in: PubMed
    Score: 0.050
  21. Time to Viral Rebound After Interruption of Modern Antiretroviral Therapies. Clin Infect Dis. 2022 03 09; 74(5):865-870.
    View in: PubMed
    Score: 0.049
  22. Non-invasive plasma glycomic and metabolic biomarkers of post-treatment control of HIV. Nat Commun. 2021 06 29; 12(1):3922.
    View in: PubMed
    Score: 0.047
  23. Increased glucose transporter-1 expression on intermediate monocytes from HIV-infected women with subclinical cardiovascular disease. AIDS. 2017 01 14; 31(2):199-205.
    View in: PubMed
    Score: 0.035
  24. Glucose transporter 1-expressing proinflammatory monocytes are elevated in combination antiretroviral therapy-treated and untreated HIV+ subjects. J Immunol. 2014 Dec 01; 193(11):5595-603.
    View in: PubMed
    Score: 0.030
  25. HIV infection induces age-related changes to monocytes and innate immune activation in young men that persist despite combination antiretroviral therapy. AIDS. 2012 Apr 24; 26(7):843-53.
    View in: PubMed
    Score: 0.025
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.